Safety profiles of old and new antimicrobials for the treatment of MRSA infections

References

• Weber JT. Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2005;41(Suppl 4):S269–S272.
   PubMed Web of Science ®Google Scholar
• Kallen AJ, Mu Y, Bulens S, et al. Health care-associated invasive MRSA infections, 2005-2008. JAMA. 2010;304:641–648.
   PubMed Web of Science ®Google Scholar
• Kock R, Becker K, Cookson B, et al. Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill. 2010;15:19688.
   PubMedGoogle Scholar
• Talan DA, Krishnadasan A, Gorwitz RJ, et al. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin Infect Dis. 2011;53:144–149.
   PubMed Web of Science ®Google Scholar
• Morrissey I, Leakey A, Northwood JB. In vitro activity of ceftaroline and comparator antimicrobials against European and Middle East isolates from complicated skin and skin-structure infections collected in 2008-2009. Int J Antimicrob Agents. 2012;40:227–234.
   PubMed Web of Science ®Google Scholar
• Johnson AP. Methicillin-resistant Staphylococcus aureus: the European landscape. J Antimicrob Chemother. 2011;66(Suppl 4):iv43–iv48.
   PubMed Web of Science ®Google Scholar
• Shurland S, Zhan M, Bradham DD, et al. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol. 2007;28:273–279.
   PubMed Web of Science ®Google Scholar
• Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36:53–59.
   PubMed Web of Science ®Google Scholar
• Otter JA, French GL. Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe. Lancet Infect Dis. 2010;10:227–239.
   PubMed Web of Science ®Google Scholar
• Hersh AL, Chambers HF, Maselli JH, et al. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med. 2008;168:1585–1591.
   PubMed Web of Science ®Google Scholar
• Viallon A, Marjollet O, Berthelot P, et al. Risk factors associated with methicillin-resistant Staphylococcus aureus infection in patients admitted to the ED. Am J Emerg Med. 2007;25:880–886.
   PubMed Web of Science ®Google Scholar
• Stevens AM, Hennessy T, Baggett HC, et al. Methicillin-resistant Staphylococcus aureus carriage and risk factors for skin infections, Southwestern Alaska, USA. Emerg Infect Dis. 2010;16:797–803.
   PubMed Web of Science ®Google Scholar
• Cesur S, Cokca F. Nasal carriage of methicillin-resistant Staphylococcus aureus among hospital staff and outpatients. Infect Control Hosp Epidemiol. 2004;25:169–171.
   PubMed Web of Science ®Google Scholar
• Popovich KJ, Weinstein RA. Commentary: the graying of methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol. 2009;30:9–12.
   PubMed Web of Science ®Google Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:285–292.
   PubMed Web of Science ®Google Scholar
• Nathwani D, Morgan M, Masterton RG, et al. Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother. 2008;61:976–994.
   PubMed Web of Science ®Google Scholar
• Murray KP, Zhao JJ, Davis SL, et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study. Clin Infect Dis. 2013;56:1562–1569.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012;54:621–629.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Sniezek G, Schweizer F, et al. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Drugs. 2009;69:809–831.
   PubMed Web of Science ®Google Scholar
• Talbot GH, Thye D, Das A, et al. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2007;51:3612–3616.
   PubMed Web of Science ®Google Scholar
• Ceftaroline fosamil (Teflaro) – a new IV cephalosporin. Med Lett Drugs Ther. 2011;53:5–6.
   PubMed Web of Science ®Google Scholar
• Corey GR, Wilcox MH, Talbot GH, et al. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl 4):iv41–iv51.
   PubMed Web of Science ®Google Scholar
• Wilcox MH, Corey GR, Talbot GH, et al. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl 4):iv53–iv65.
   PubMed Web of Science ®Google Scholar
• Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;51:641–650.
   PubMed Web of Science ®Google Scholar
• Corey GR, Good S, Jiang H, et al. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2015;60:254–262.
   PubMed Web of Science ®Google Scholar
• Corey GR, Jiang H, Moeck G. Dalbavancin or oritavancin for skin infections. N Engl J Med. 2014;371:1162–1163.
   PubMed Web of Science ®Google Scholar
• Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370:2169–2179.
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008;46:1683–1693.
   PubMed Web of Science ®Google Scholar
• Torres A, Rubinstein E, Corey GR, et al. Analysis of phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure. J Antimicrob Chemother. 2014;69:1119–1126.
   PubMed Web of Science ®Google Scholar
• Queenan AM, Shang W, Kania M, et al. Interactions of ceftobiprole with beta-lactamases from molecular classes A to D. Antimicrob Agents Chemother. 2007;51:3089–3095.
   PubMed Web of Science ®Google Scholar
• Nicholson SC, Welte T, File TM Jr., et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents. 2012;39:240–246.
   PubMed Web of Science ®Google Scholar
• Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis. 2006;43:180–187.
   PubMed Web of Science ®Google Scholar
• Senneville E, Legout L, Valette M, et al. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J Antimicrob Chemother. 2004;54:798–802.
   PubMed Web of Science ®Google Scholar
• Lin YH, Wu VC, Tsai IJ, et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents. 2006;28:345–351.
   PubMed Web of Science ®Google Scholar
• Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis. 2003;36:159–168.
   PubMed Web of Science ®Google Scholar
• Casapao AM, Davis SL, Barr VO, et al. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother. 2014;58:2541–2546.
   PubMed Web of Science ®Google Scholar
• Varada NL, Sakoulas G, Lei LR, et al. Agranulocytosis with ceftaroline high-dose monotherapy or combination therapy with clindamycin. Pharmacotherapy. 2015;35:608–612.
   PubMed Web of Science ®Google Scholar
• LaVie K, Anderson SW, O’Neal HR Jr, et al. Neutropenia associated with long term ceftaroline use. Antimicrob Ag Chemother. 2016;60(1). doi:10.1128/AAC.01471-15.
   Web of Science ®Google Scholar
• Jain R, Chan JD, Rogers L, et al. High incidence of discontinuations due to adverse events in patients treated with ceftaroline. Pharmacotherapy. 2014;34(7):758–763.
   PubMed Web of Science ®Google Scholar
• Panagiotidis G, Backstrom T, Asker-Hagelberg C, et al. Effect of ceftaroline on normal human intestinal microflora. Antimicrob Agents Chemother. 2010;54:1811–1814.
   PubMed Web of Science ®Google Scholar
• Walkty A, Adam HJ, Laverdiere M, et al. In vitro activity of ceftobiprole against frequently encountered aerobic and facultative gram-positive and gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis. 2011;69:348–355.
   PubMed Web of Science ®Google Scholar
• Noel GJ, Bush K, Bagchi P, et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis. 2008;46:647–655.
   PubMed Web of Science ®Google Scholar
• Awad SS, Rodriguez AH, Chuang YC, et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis. 2014;59:51–61.
   PubMed Web of Science ®Google Scholar
• Levine DP. Vancomycin: a history. Clin Infect Dis. 2006;42(Suppl 1):S5–S12.
   PubMed Web of Science ®Google Scholar
• Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46:193–200.
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29:1275–1279.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Patel N, Lomaestro BM, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49:507–514.
   PubMed Web of Science ®Google Scholar
• Gupta A, Biyani M, Khaira A. Vancomycin nephrotoxicity: myths and facts. Neth J Med. 2011;69:379–383.
   PubMed Web of Science ®Google Scholar
• Dieterich C, Puey A, Lin S, et al. Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates. Toxicol Sci. 2009;107:258–269.
   PubMed Web of Science ®Google Scholar
• Van Hal SJ, Paterson DL, Lodise TP, Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57:734–744.
   PubMed Web of Science ®Google Scholar
• Elyasi S, Khalili H, Dashti-Khavidaki S, et al. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol. 2012;68:1243–1255.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yang XY, Zeckel M, et al. Risk of hepatic events in patients treated with vancomycin in clinical studies: a systematic review and meta-analysis. Drug Saf. 2011;34:73–82.
   PubMed Web of Science ®Google Scholar
• Black E, Lau TT, Ensom MH. Vancomycin-induced neutropenia: is it dose- or duration-related? Ann Pharmacother. 2011;45:629–638.
   PubMed Web of Science ®Google Scholar
• Janknegt R. Teicoplanin in perspective. A critical comparison with vancomycin. Pharm Weekbl Sci. 1991;13:153–160.
   PubMedGoogle Scholar
• Cavalcanti AB, Goncalves AR, Almeida CS, et al. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev. 2010;6:CD007022.
   Google Scholar
• Hahn-Ast C, Glasmacher A, Arns A, et al. An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia: is the different toxicity profile clinically relevant? Infection. 2008;36:54–58.
   PubMed Web of Science ®Google Scholar
• Hung YP, Lee NY, Chang CM, et al. Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: a retrospective chart review. Clin Ther. 2009;31:1977–1986.
   PubMed Web of Science ®Google Scholar
• Wilson AP. Comparative safety of teicoplanin and vancomycin. Int J Antimicrob Agents. 1998;10:143–152.
   PubMed Web of Science ®Google Scholar
• Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother. 2009;53:4069–4079.
   PubMed Web of Science ®Google Scholar
• Ueda T, Takesue Y, Nakajima K, et al. High-dose regimen to achieve novel target trough concentration in teicoplanin. J Infect Chemother. 2014;20:43–47.
   PubMed Web of Science ®Google Scholar
• Matthews PC, Chue AL, Wyllie D, et al. Increased teicoplanin doses are associated with improved serum levels but not drug toxicity. J Infect. 2014;68:43–49.
   PubMed Web of Science ®Google Scholar
• Natsumoto B, Yokota K, Omata F, et al. Risk factors for linezolid-associated thrombocytopenia in adult patients. Infection. 2014;42:1007–1012.
   PubMed Web of Science ®Google Scholar
• Attassi K, Hershberger E, Alam R, et al. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis. 2002;34:695–698.
   PubMed Web of Science ®Google Scholar
• Im JH, Baek JH, Kwon HY, et al. Incidence and risk factors of linezolid-induced lactic acidosis. Int J Infect Dis. 2015;31:47–52.
   PubMed Web of Science ®Google Scholar
• Quinn DK, Stern TA. Linezolid and serotonin syndrome. Prim Care Companion J Clin Psychiatry. 2009;11:353–356.
   PubMedGoogle Scholar
• Legout L, Senneville E, Gomel JJ, et al. Linezolid-induced neuropathy. Clin Infect Dis. 2004;38:767–768.
   PubMed Web of Science ®Google Scholar
• Hazlewood KA, Brouse SD, Pitcher WD, et al. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med. 2010;123:182, e181–e187.
   Web of Science ®Google Scholar
• Sivagnanam S, Deleu D. Red man syndrome. Crit Care. 2003;7:119–120.
   PubMed Web of Science ®Google Scholar
• Wang SZ, Hu JT, Zhang C, et al. The safety and efficacy of daptomycin versus other antibiotics for skin and soft-tissue infections: a meta-analysis of randomised controlled trials. BMJ Open. 2014;4:e004744.
   PubMed Web of Science ®Google Scholar
• Fu J, Ye X, Chen C, et al. The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infections. PLoS One. 2013;8:e58240.
   PubMed Web of Science ®Google Scholar
• Chavanet P. The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia. Med Mal Infect. 2013;43:451–455.
   PubMed Web of Science ®Google Scholar
• Shaw JP, Seroogy J, Kaniga K, et al. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother. 2005;49:195–201.
   PubMed Web of Science ®Google Scholar
• Hope R, Chaudhry A, Adkin R, et al. In vitro activity of telavancin and comparators against selected groups of gram-positive cocci. Int J Antimicrob Agents. 2013;41:213–217.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Sader HS, Jones RN. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008). Int J Antimicrob Agents. 2010;36:374–379.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Mendes RE, Sader HS, et al. Telavancin activity against gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia. J Antimicrob Chemother. 2010;65:2396–2404.
   PubMed Web of Science ®Google Scholar
• Putnam SD, Sader HS, Moet GJ, et al. Worldwide summary of telavancin spectrum and potency against gram-positive pathogens: 2007 to 2008 surveillance results. Diagn Microbiol Infect Dis. 2010;67:359–368.
   PubMed Web of Science ®Google Scholar
• Hooper CY, Smith WJ. Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA). Ther Clin Risk Manag. 2012;8:131–137.
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis. 2011;52:31–40.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Mikulska M, Righi E, et al. The role of telavancin in the treatment of MRSA infections in hospital. Expert Opin Investig Drugs. 2009;18:521–529.
   PubMed Web of Science ®Google Scholar
• Worboys PD, Wong SL, Barriere SL. Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment. Eur J Clin Pharmacol. 2015;71:707–714.
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, O’Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis. 2005;40:1601–1607.
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Chu VH, O’Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother. 2006;50:862–867.
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Corey GR, Stryjewski ME, et al. Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia. Expert Opin Pharmacother. 2011;12:2737–2750.
   PubMed Web of Science ®Google Scholar
• Corey GR, Rubinstein E, Stryjewski ME, et al. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus. Clin Infect Dis. 2015;60:787–796.
   PubMed Web of Science ®Google Scholar
• Polyzos KA, Mavros MN, Vardakas KZ, et al. Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis. PLoS One. 2012;7:e41870.
   PubMed Web of Science ®Google Scholar
• Zyvoxid package insert [Internet]. Pfizer Laboratories (Pty) Ltd; 2016 [cited 2016 Jan 21]. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=1045.
   Google Scholar
• Peterson J. Important drug warning: letter to health care professionals. Peapack (NJ): Pharmacia Corp. 2001. Available from: http://www.fda.gov/medwatch/safety/2001/Zyvox.pdf.
   Google Scholar
• Marcos LA, Camins BC, Ritchie DJ, et al. Acute renal insufficiency during telavancin therapy in clinical practice. J Antimicrob Chemother. 2012;67:723–726.
   PubMed Web of Science ®Google Scholar
• Masterton R, Cornaglia G, Courvalin P, et al. The clinical positioning of telavancin in Europe. Int J Antimicrob Agents. 2015;45:213–220.
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Citron DM, Merriam CV, et al. In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria. Antimicrob Agents Chemother. 2003;47:1968–1971.
   PubMed Web of Science ®Google Scholar
• Jones RN, Sader HS, Flamm RK. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis. 2013;75:304–307.
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Adam HJ, Poutanen SM, et al. Canadian antimicrobial resistance A. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis. 2011;69:342–347.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Trapp S, Gin AS, et al. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of gram-positive infections. Expert Rev Anti Infect Ther. 2008;6:67–81.
   PubMed Web of Science ®Google Scholar
• Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41:1407–1415.
   PubMed Web of Science ®Google Scholar
• Dunne MW, Zhou M, Darpo B. A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections. Int J Antimicrob Agents. 2015;45:393–398.
   PubMed Web of Science ®Google Scholar
• Dunne MW, Puttagunta S, Giordano P, et al. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2015;pii:civ982.
   Google Scholar
• Morrissey I, Seifert H, Canton R, et al. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and beta-haemolytic streptococci collected from western European countries in 2011. J Antimicrob Chemother. 2013;68:164–167.
   PubMed Web of Science ®Google Scholar
• Tally FP, DeBruin MF. Development of daptomycin for gram-positive infections. J Antimicrob Chemother. 2000;46:523–526.
   PubMed Web of Science ®Google Scholar
• Allen NE, Alborn WE Jr., Hobbs JN Jr. Inhibition of membrane potential-dependent amino acid transport by daptomycin. Antimicrob Agents Chemother. 1991;35:2639–2642.
   PubMed Web of Science ®Google Scholar
• Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673–1681.
   PubMed Web of Science ®Google Scholar
• Fowler VG Jr., Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653–665.
   PubMed Web of Science ®Google Scholar
• Oleson FB Jr., Berman CL, Kirkpatrick JB, et al. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother. 2000;44:2948–2953.
   PubMed Web of Science ®Google Scholar
• Tally FP, Zeckel M, Wasilewski MM, et al. Daptomycin: a novel agent for Gram-positive infections. Expert Opin Investig Drugs. 1999;8:1223–1238.
   PubMedGoogle Scholar
• Sauermann R, Rothenburger M, Graninger W, et al. Daptomycin: a review 4 years after first approval. Pharmacology. 2008;81:79–91.
   PubMed Web of Science ®Google Scholar
• Benvenuto M, Benziger DP, Yankelev S, et al. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006;50:3245–3249.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Villa G, Ansaldi F, et al. Risk factors associated with the onset of daptomycin non-susceptibility in Staphylococcus aureus infections in critically ill patients. Intensive Care Med. 2015;41:366–368.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Nicco E, Ginocchio F, et al. High-dose daptomycin in documented Staphylococcus aureus infections. Int J Antimicrob Agents. 2010;36:459–461.
   PubMed Web of Science ®Google Scholar
• Moise PA, Hershberger E, Amodio-Groton MI, et al. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy. Ann Pharmacother. 2009;43:1211–1219.
   PubMed Web of Science ®Google Scholar
• Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis. 2009;49:177–180.
   PubMed Web of Science ®Google Scholar
• Kullar R, Davis SL, Levine DP, et al. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy. 2011;31:527–536.
   PubMed Web of Science ®Google Scholar
• Perrottet N, Steinrucken J, Chan M, et al. Efficacy and safety of high-dose daptomycin (>6mg/kg) for complicated bone and joint infections and implant-associated infections caused by gram-positive bacteria. Int J Antimicrob Agents. 2015;46:480–482.
   PubMed Web of Science ®Google Scholar
• Yusuf E, Perrottet N, Orasch C, et al. Daptomycin-associated eosinophilic pneumonia in two patients with prosthetic joint infection. Surg Infect (Larchmt). 2014;15(6):834–837.
   PubMed Web of Science ®Google Scholar
• Miller BA, Gray A, LeBlanc TW, et al. Acute Eosinophilic Pneumonia Secondary to Daptomycin: A Report of Three Cases. Clin Infect Dis. 2010;50(11):e63–e68.
   Google Scholar
• Lal Y, Assimacopoulos AP. Two cases of daptomycin-induced eosinophilic pneumonia and chronic pneumonitis. Clin Infect Dis. 2010;50:737–740.
   PubMed Web of Science ®Google Scholar
• Bozdogan B, Appelbaum PC. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents. 2004;23:113–119.
   PubMed Web of Science ®Google Scholar
• Ford CW, Hamel JC, Stapert D, et al. Oxazolidinones: new antibacterial agents. Trends Microbiol. 1997;5:196–200.
   PubMed Web of Science ®Google Scholar
• Brickner SJ, Hutchinson DK, Barbachyn MR, et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J Med Chem. 1996;39:673–679.
   PubMed Web of Science ®Google Scholar
• Welshman IR, Sisson TA, Jungbluth GL, et al. Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm Drug Dispos. 2001;22:91–97.
   PubMed Web of Science ®Google Scholar
• Li Z, Willke RJ, Pinto LA, et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy. 2001;21:263–274.
   PubMed Web of Science ®Google Scholar
• Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother. 2003;47:2775–2780.
   PubMed Web of Science ®Google Scholar
• MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother. 2003;51(Suppl 2):ii17–25.
   PubMedGoogle Scholar
• Wynalda MA, Hauer MJ, Wienkers LC. Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes. Drug Metab Dispos. 2000;28:1014–1017.
   PubMed Web of Science ®Google Scholar
• Antal EJ, Hendershot PE, Batts DH, et al. Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine. J Clin Pharmacol. 2001;41:552–562.
   PubMed Web of Science ®Google Scholar
• Hendershot PE, Antal EJ, Welshman IR, et al. Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr. J Clin Pharmacol. 2001;41:563–572.
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Isturiz R, Standiford HC, et al., et al. Worldwide assessment of linezolid’s clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother. 2003;47:1824–1831.
   PubMed Web of Science ®Google Scholar
• Lavery S, Ravi H, McDaniel WW, et al. Linezolid and serotonin syndrome. Psychosomatics. 2001;42:432–434.
   PubMed Web of Science ®Google Scholar
• French G. Safety and tolerability of linezolid. J Antimicrob Chemother. 2003;51(Suppl 2):ii45–53.
   PubMedGoogle Scholar
• Soriano A, Miro O, Mensa J. Mitochondrial toxicity associated with linezolid. N Engl J Med. 2005;353:2305–2306.
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P, Cojutti P, et al. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother. 2012;67(8):2034–2042.
   PubMed Web of Science ®Google Scholar
• Nukui Y, Hatakeyama S, Okamoto K, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother. 2013;68(9):2128–2133.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Takeshita A, Ikawa K, et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents. 2010;36(2):179–181.
   PubMed Web of Science ®Google Scholar
• Cohen N, Mihu CN, Seo SK, et al. Hematologic safety profile of linezolid in the early periengraftment period after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:1337–1341.
   PubMed Web of Science ®Google Scholar
• Smith PF, Birmingham MC, Noskin GA, et al. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. Ann Oncol. 2003;14:795–801.
   PubMed Web of Science ®Google Scholar
• Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002;46:2723–2726.
   PubMed Web of Science ®Google Scholar
• Gould FK. Linezolid: safety and efficacy in special populations. J Antimicrob Chemother. 2011;66(Suppl 4):iv3–iv6.
   PubMed Web of Science ®Google Scholar
• Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. J Infect. 2009;59(Suppl 1):S59–74.
   PubMed Web of Science ®Google Scholar
• Apodaca AA, Rakita RM. Linezolid-induced lactic acidosis. N Engl J Med. 2003;348:86–87.
   PubMed Web of Science ®Google Scholar
• Keel RA, Tessier PR, Crandon JL, et al. Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model. Antimicrob Agents Chemother. 2012;56:4403–4407.
   PubMed Web of Science ®Google Scholar
• Moran GJ, Fang E, Corey GR, et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014;14:696–705.
   PubMed Web of Science ®Google Scholar
• Urbina O, Ferrandez O, Espona M, et al. Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections. Drug Des Devel Ther. 2013;7:243–265.
   PubMed Web of Science ®Google Scholar
• Flanagan S, Bartizal K, Minassian SL, et al. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother. 2013;57:3060–3066.
   PubMed Web of Science ®Google Scholar
• Das D, Tulkens PM, Mehra P, et al. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary. Clin Infect Dis. 2014;58(Suppl 1):S51–57.
   PubMed Web of Science ®Google Scholar
• Prokocimer P, De Anda C, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013;309:559–569.
   PubMed Web of Science ®Google Scholar
• Lawrence L, Danese P, DeVito J, et al. In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. Antimicrob Agents Chemother. 2008;52:1653–1662.
   PubMed Web of Science ®Google Scholar
• ClinicalTrial.com. Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia. Identifier NCT00640926.
   Google Scholar
• ClinicalTrial.com. Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections. Identifier NCT00646958.
   Google Scholar
• Shaw KJ, Barbachyn MR. The oxazolidinones: past, present, and future. Ann N Y Acad Sci. 2011;1241:48–70.
   PubMed Web of Science ®Google Scholar
• Elyasi S, Khalili H, Hatamkhani S, et al. Prevention of vancomycin induced nephrotoxicity: a review of preclinical data. Eur J Clin Pharmacol. 2013;69:747–754.
   PubMed Web of Science ®Google Scholar
• Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl 4):iv67–iv71.
   PubMed Web of Science ®Google Scholar